The Critical Role of CDMOs in Scaling Personalized Medicine The rapid clinical advancement of personalized therapeutics has created a unique bottleneck in the biotechnology industry: manufacturing. While the scientific community has mastered the art of cellular engineering in clinical trials, scaling these processes for global commercialization remains incredibly difficult. In the realm of autologous cell therapy, scaling up does not mean making larger...
0 Distribuiri
7 Views
0 previzualizare